this post was submitted on 11 Aug 2023
565 points (94.3% liked)
Asklemmy
44152 readers
690 users here now
A loosely moderated place to ask open-ended questions
If your post meets the following criteria, it's welcome here!
- Open-ended question
- Not offensive: at this point, we do not have the bandwidth to moderate overtly political discussions. Assume best intent and be excellent to each other.
- Not regarding using or support for Lemmy: context, see the list of support communities and tools for finding communities below
- Not ad nauseam inducing: please make sure it is a question that would be new to most members
- An actual topic of discussion
Looking for support?
Looking for a community?
- Lemmyverse: community search
- sub.rehab: maps old subreddits to fediverse options, marks official as such
- [email protected]: a community for finding communities
~Icon~ ~by~ ~@Double_[email protected]~
founded 5 years ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
I disagree with your view on IP, at least for pharmaceuticals. For most drugs, the exclusivity period is only 5 years, after which generic companies reverse engineer the product with ease and create a low-cost alternative. Without this period allowing pharma companies to make their money, there'd be no reason to invest the billions upon billions of dollars into R&D to discover and develop the drug in the first place. Most drug candidates fail, and the wins are what prop up the whole industry.
I'm not defending price gouging and I think all governments should control pricing, preferably with a single payer system (looking at you USA), but we would be so much further behind without patent protection. Especially for orphan diseases.
Don't really agree with you on IP for most creative purposes either. There should be a reasonable length of time you get exclusive rights to something you create. But this doesn't excuse Disney's stranglehold on the mouse.
Yeah with pharma in particular you need that initial profitability, as you say.
Additionally...
This doesn't really make sense. Shenzen company's might have copied products developed by other companies, but surely you still need another company to invest the R & D initially in order to have something to copy.
Consumer products don't "evolve". Developing and producing are two different processes. If there's no IP then there's only an incentive to produce things, and no incentive to develop them. I think this is especially true of pharmaceuticals given that there's no incremental / evolutionary pathway to discovering new drugs and the costs of conducting trials et cetera is preclusive.